

## Accepted Manuscript

Oxidative Stress Adaptation in Aggressive Prostate Cancer May Be Counteracted by The Reduction of Glutathione Reductase

Mariana Freitas, Inês Baldeiras, Teresa Proença, Vera Alves, Anabela Mota-Pinto, Ana Sarmiento-Ribeiro

PII: S2211-5463(12)00018-6  
DOI: <http://dx.doi.org/10.1016/j.fob.2012.05.001>  
Reference: FOB 23

To appear in: *FEBS Open Bio*

Received Date: 16 March 2012  
Revised Date: 10 May 2012  
Accepted Date: 11 May 2012

Please cite this article as: Freitas, M., Baldeiras, I., Proença, T., Alves, V., Mota-Pinto, A., Sarmiento-Ribeiro, A., Oxidative Stress Adaptation in Aggressive Prostate Cancer May Be Counteracted by The Reduction of Glutathione Reductase, *FEBS Open Bio* (2012), doi: <http://dx.doi.org/10.1016/j.fob.2012.05.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **OXIDATIVE STRESS ADAPTATION IN AGGRESSIVE PROSTATE CANCER MAY**  
2 **BE COUNTERACTED BY THE REDUCTION OF GLUTATHIONE REDUCTASE**

3

4 **Authors and affiliations:** Mariana Freitas<sup>\*1,2,3</sup>, Inês Baldeiras<sup>3,4</sup>, Teresa Proença<sup>3,4</sup>, Vera Alves<sup>5</sup>,  
5 Anabela Mota-Pinto<sup>1,2</sup> and Ana Sarmiento-Ribeiro<sup>2,3,6</sup>

6

7 \*Author for correspondence:

8

9 Address for correspondence: <sup>1</sup>General Pathology Laboratory, Faculty of Medicine, University of  
10 Coimbra – Rua Larga 3004-504 Coimbra, Portugal

11 Tel: 351 239 822 547; Fax: 351 239 822 547

12

13 <sup>1</sup>General Pathology Laboratory, Faculty of Medicine, University of Coimbra – Rua Larga 3004-  
14 504 Coimbra, Portugal

15 Tel: 351 239 822 547; Fax: 351 239 822 547

16

17 <sup>2</sup>CIMAGO - Centre of Investigation in Environment, Genetics and Oncobiology, Faculty of  
18 Medicine, University of Coimbra – Apartado 9015 3001-301 Coimbra, Portugal

19 Tel: 351 239 721 478; Fax: 351 239 721 478

20

21 <sup>3</sup>CNC - Centre of Neurosciences and Cell Biology, Department of Zoology, University of  
22 Coimbra - 3004-517 Coimbra, Portugal

23 Tel: 351 239 721 478; Fax: 351 239 721 478

24

25 <sup>4</sup>Laboratory of Neurochemistry, Neurology Department, Hospital of the University of Coimbra -  
26 Praceta Prof Mota Pinto 3000-075 Coimbra, Portugal

27 Tel: 351 239 400 400; Fax: 351 239 823 907

28

29 <sup>5</sup>Immunology Laboratory, Faculty of Medicine, University of Coimbra - Rua Larga 3004-504  
30 Coimbra, Portugal

31 Tel: 351 239 824 873; Fax: 351 239 820 242

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61

<sup>6</sup>Applied Molecular Biology/ Biochemistry Laboratory and Haematology, Faculty of Medicine, University of Coimbra - Subunidade I de Ensino, Pólo III 3000-354 Coimbra, Portugal; Tel: 351 239 480 038 ; Fax: 351 239 480 048

E-mail addresses: freitas.mariana@gmail.com (\*Mariana Freitas), ines.baldeiras@sapo.pt (Inês Baldeiras), teresaproenca@huc.min-saude.pt (Teresa Proença), valves@fmed.uc.pt (Vera Alves), apinto@fmed.uc.pt (Anabela Mota-Pinto), ana.belasarmento@gmail.com (Ana Bela Sarmento-Ribeiro),

**Running title:** Glutathione reductase in prostate cancer therapy

62 **ABSTRACT**

63 Oxidative stress has been associated with prostate cancer development and progression due to an  
64 increase of reactive oxygen species (ROS). However, the mechanisms whereby ROS and the  
65 antioxidant system participate in cancer progression remain unclear.

66 In order to clarify the influence of oxidative stress in prostate cancer progression, we performed  
67 this study in two human prostate cancer cell lines, PC3 and HPV10 (from metastasis and from  
68 cancer in situ, respectively) and RWPE1 cells derived from normal prostate epithelium. Cells  
69 were treated with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and PC3 cells were also treated with diethyl maleate  
70 (DEM). The effect on cell growth, viability, mitochondria membrane potential and oxidative  
71 stress was analyzed. Oxidative stress was evaluated based on ROS production, oxidative lesion  
72 of lipids (MDA) and on determination of antioxidants, including enzyme activity of glutathione  
73 peroxidase (G1-Px), glutathione reductase (G1-Red) and on the quantification of glutathione  
74 (GSH), glutathione-s-transferase (GST) and total antioxidant status (TAS).

75 PC3 shows higher ROS production but also the highest GSH levels and G1-Red activity, possibly  
76 contributing to oxidative stress resistance. This is also associated with higher mitochondrial  
77 membrane potential, TAS and lower lipid peroxidation. On the other hand, we identified G1-Red  
78 activity reduction as a new strategy in overcoming oxidative stress resistance, by inducing H<sub>2</sub>O<sub>2</sub>  
79 cytotoxicity. Therefore these results suggest G1-Red activity reduction as a new potential  
80 therapeutic approach, in prostate cancer.

81  
82 **KEY WORDS:** Prostate cancer, oxidative stress (OS), reactive oxygen species (ROS),  
83 glutathione (GSH), glutathione reductase (G1-Red), cell lines

84

85

86

87

88

89

90

91

## 92 1. INTRODUCTION

93

94 Prostate cancer is still the most frequently diagnosed malignant disease and the second leading  
95 cause of cancer-related mortality in men in most Western countries [1, 2].

96 Although the causes of the high incidence of prostate cancer are poorly understood,  
97 epidemiological, experimental and clinical studies, suggest that oxidative stress (OS) plays a  
98 major role in explaining prostate cancer development and progression [3-12]. OS, defined as an  
99 imbalance between reactive oxygen species (ROS) production and antioxidant defences [13, 14]  
100 has been linked to some prostate cancer risk factors including diet intake [15-18], recurrent  
101 inflammation and aging [19-21].

102 ROS, generated *in vivo*, include free radicals and non-radicals. Free radicals are molecules  
103 containing unpaired electrons as superoxide anion ( $O_2^-$ ), hydroxyl radical ( $\cdot OH$ ) and peroxide  
104 radicals [22]. Non-radicals such as singlet molecular oxygen ( $O_2$ ), nitrogen oxide ( $NO_x$ ) and  
105 hydrogen peroxide ( $H_2O_2$ ) can easily give rise to oxygen radicals. Namely,  $H_2O_2$  leads to  $\cdot OH$   
106 formation, in the presence of transition metals [22, 23]. ROS play an essential role in signal  
107 transduction pathways [24], cell cycle progression [25-30], gene transcription [31], cell  
108 differentiation [28, 32] and death (for review see Martindale and Holbrook [33]). However, an  
109 increase in ROS production and/or a decrease in antioxidant network may induce to severe OS  
110 leading to biomolecules damage such as DNA, proteins and lipids [3-12, 34, 35]. On the other  
111 hand, oxidative damage of DNA is thought to play a critical role in all stages of carcinogenesis  
112 [36].

113 Moreover, the major feature of radiation therapy that is a standard treatment of prostate cancer is  
114 based in ROS generation leading to oxidative damage [37]. However, metastatic prostate cancer  
115 cells may be resistant to radiotherapy, suggesting that the antioxidant system may play an  
116 important role in circumventing radiation cytotoxicity [34], thus, contributing for therapy failure.  
117 Therefore new therapeutic approaches related, in part, with OS modulation, have been suggested,  
118 namely, by Freitas *et al* [38].

119 The antioxidant network comprises the enzymes superoxide dismutase (SOD), catalase,  
120 glutathione peroxidase (Gl-Px), glutathione reductase (Gl-Red) and glutathione-s-transferase  
121 (GST) that play an important role in prostate cancer prevention, protecting cells from genomic  
122 damage mediated by carcinogens and ROS generated during inflammation. Other molecules, as

123 vitamins E and C and reduced glutathione (GSH) complement the antioxidant enzymes and are  
124 capable of neutralising ROS [22]. GSH plays a critical role in cellular redox maintenance. Gl-Px  
125 catalyzes the reduction of peroxides and the formation of oxidized glutathione (GSSG) [7]. Gl-  
126 Red uses NADPH and  $H^+$  to reduce the GSSG back to GSH [9]. This paper investigates whether  
127 ROS (peroxides) and antioxidant defences contribute to prostate cancer progression and how the  
128 OS modulation may be a new prostate cancer therapeutic approach.

129

## 130 **2. MATERIALS AND METHODS**

131

### 132 **2.1. Cell culture conditions**

133

134 Human prostate cancer cell lines derived from localized adenocarcinoma, from (HPV10) [39],  
135 from bone metastasis (PC3) [40] and from the normal prostate epithelium (RWPE1) [41] were  
136 purchased from the American Type Culture Collection (ATCC) and cultured in optimum growth  
137 conditions.

138 RWPE1 and HPV10 cells were grown in keratinocytes medium (Gibco) supplemented with  
139 5ng/ml of human recombinant epidermal growth factor (rEGF) (Gibco) and 0.05 mg/ml of  
140 bovine pituitary extract (BPE) (Invitrogen, formerly Gibco-BRL). PC3 cells were grown in RPMI  
141 1640 medium (Sigma) with 10 % (v/v) heat-inactivated fetal bovine serum (FBS) (Biochrom)  
142 and 2 mM L-glutamine (Sigma). Both medium, were supplemented with 100U/ml Penicillin,  
143 100 $\mu$ g/ml Streptomycin and with 5 $\mu$ g/ml Kanamycin (Sigma).

144 Cells were maintained in a 95% humidified incubator with 5%  $CO_2$  at 37°C and were passaged  
145 with trypsinization every fourth day. For assays RWPE1 and HPV10 were plated at a density of  
146  $5 \times 10^5$  cells/ml whereas PC3 were seeded at a density of  $3 \times 10^5$  cells/ml. After being cultured for  
147 24h, the cells were washed once with fresh assay medium and treated for 24 to 72 hours with  
148 hydrogen peroxide ( $H_2O_2$ )(10nM-500 $\mu$ M). PC3 were also treated with diethyl maleate (DEM)  
149 (Sigma).

150

### 151 **2.2. Cell proliferation analysis**

152

153 Cell proliferation was measured by the colorimetric MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-  
154 diphenyltetrazolium bromide) (Sigma) assay method that quantifies the reduction of the yellow  
155 tetrazolium salt to purple formazan crystals by the mitochondria of viable cells [42]. Briefly,  
156 untreated and treated cells were washed with PBS (Gibco) that was replaced by MTT (0.5mg/ml)  
157 supplemented with 1mM CaCl<sub>2</sub> (Sigma). The cells were then incubated at 37°C for 2 h.  
158 Formazan crystals were dissolved with HCl 0.04 M in isopropanol. Absorbance from the  
159 resultant coloured solution was measured at 570 nm [38].

160

### 161 **2.3. Flow Cytometry studies**

162

163 Each 24h of incubation, 1 x 10<sup>6</sup> of treated cells and corresponding controls, were collected by  
164 trypsinization and washed two times in PBS buffer, by centrifugation, for further acquisition and  
165 analysis in a FACScalibur (488nm and 635nm), using the Cellquest and Paint-a-gate software  
166 (BD Bioscience). Attached cells are considered as viable and were selected for. mitochondrial  
167 membrane potential (MMP) and ROS analysis. For cell viability and death analysis we also  
168 collected the suspension cells.

169 Specimens were prepared in triplicate and at least 10000 events were collected.

170

#### 171 **2.3.1. Cell viability and death: detection of apoptosis or necrosis using Annexin** 172 **V/Propidium iodide incorporation**

173

174 For identification of cell death by apoptosis or necrosis, suspension and attached cells were  
175 collected for the assay. After washed, the collected cells (1 x 10<sup>5</sup>) were resuspended in 100µL of  
176 binding buffer (0.025 M CaCl<sub>2</sub>, 1.4 M NaCl, 0.1 M HEPES) containing 5 µL annexin-V APC and  
177 2µL propidium iodide 3µM (PI) (Invitrogen-Molecular Probes). Samples were kept in the dark at  
178 room temperature for 15 minutes, according to manufacturer's instruction [43] and Freitas *et al.*  
179 [38].

180

#### 181 **2.3.2. Mitochondrial membrane potential (MMP) analysis**

182

183 In order to detect MMP, the cells were labelled with the fluorescent probe 5,5',6,6'-tetrachloro-  
184 1,1'3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC1) (Cell Technology) according to  
185 manufacture's instructions as previously performed by Freitas *et al.* [38]. Briefly  $5 \times 10^5$  cells  
186 were resuspended in 0.5 ml of 1x JC-1 reagent solution and then incubated for 15 minutes, at  
187 37°C in a 5% CO<sub>2</sub> chamber. The cells were washed two times with 2 ml 1 x assay buffer under  
188 centrifugation at 1500 rpm, resuspended in 0.5 ml 1x assay buffer and were analyzed by flow  
189 cytometry.

190 The lipophilic cationic probe JC1, developed by Cossariza *et al.* [44] is able to selectively enter  
191 in the intact mitochondria, forming J-aggregates (J-A), which are associated with a large shift in  
192 emission (590 nm). However, in lower polarized mitochondrial membrane, JC1 accumulates in  
193 the cytoplasm in the monomeric form (J-M), emitting at 527 nm after excitation at 490 nm.  
194 Therefore the ratio J-M/ J-A is inversely correlated with MMP.

195

## 196 **2.4. OS evaluation**

197

198 OS was evaluated by measuring ROS production, antioxidant capacity and lipid peroxidation.

199

### 200 **2.4.1. Reactive oxygen species measurements**

201

202 We evaluate ROS levels by labelling  $5 \times 10^5$  cells with 5 μM 2,7 dichlorodihydrofluorescein  
203 diacetate (DCFH<sub>2</sub>-DA) (Sigma) according to adaptations of previously procedures [38, 45-47].  
204 The cells were incubated during 1h at 37°C, in the dark, washed 2 times in 0.5 ml phosphate-  
205 buffered saline (PBS) and were collected through centrifugation at 1500 rpm. The cells were  
206 then resuspended in 0.5ml PBS for flow cytometry analyses. This methodology is based on the  
207 conversion of (DCFH<sub>2</sub>-DA) in DCFH<sub>2</sub> by intracellular esterases and consequent formation of the  
208 highly fluorescent 2,7-dichlorofluorescein (DCF) by ROS. The resultant green fluorescence is  
209 proportional to the intracellular level of ROS, upon excitation at 488 nm. Moreover total  
210 population was considered for ROS measurements.

211

### 212 **2.4.2. Antioxidant capacity**

213

#### 214 **2.4.2.1. Cell lysates preparation**

215  
216 After 24h, treated cells were washed 2 times with PBS, scraped off the flasks and resuspended in  
217 1 ml PBS. Cells were then subjected to 3 pulses of sonication for 10 seconds with 1 minute  
218 intermittent cooling on ice in a Bandelin Sonorex.

219 Protein concentration was assessed using bicinchonic acid assay kit (Sigma) according to  
220 manufacture's instruction. The lysates had been stored at -80°C before usage.

221

#### 222 **2.4.2.2. Reduced glutathione assay**

223  
224 Reduced glutathione (GSH) was performed using a kit from Oxisresearch according to  
225 manufacture's instructions. This method is based on the formation of a chromophoric thione that  
226 is proportional to GSH concentration at 420 nm [48]. Results are expressed as  $\mu\text{mol}$  of GSH per  
227 gram of protein ( $\mu\text{mol/g prot}$ ).

228

#### 229 **2.4.2.3. Antioxidant enzymes determinations**

230

##### 231 **2.4.2.3.1. Glutathione peroxidase**

232

233 Glutathione peroxidase (Gl-Px) activity was evaluated by spectrophotometry using tert-  
234 butylperoxide as a substrate [49], monitoring the formation of oxidized glutathione, through the  
235 quantification of the oxidation of NADPH to  $\text{NADP}^+$  at 340 nm. Results are expressed in  
236 international units of enzyme per gram of protein (U/g prot).

237

##### 238 **2.4.2.3.2. Glutathione reductase**

239

240 Glutathione reductase (Gl-Red) activity was determined using GSSG as a substrate and  
241 monitoring its reduction to GSH through quantification of NADPH oxidation at 340 nm [50] in a  
242 thermostated spectrophotometer UVIKON 933 UV/ Visible, at 37°C. Gl-Red activity was  
243 expressed in international units of enzyme per gram of protein (U/g prot)

244

#### 245 **2.4.2.3.3. Glutathione-s-transferase**

246  
247 Glutathione-s-transferase (GST) levels, namely from the Pi subgroup (GST-Pi), were quantified  
248 by an Enzyme Immuno Assay (EIA) according to manufacture's instructions  
249 (Immunodiagnostick) at 450nm. This method is based in the competition of GST samples and  
250 GST from plate for a rabbit antibody binding. After a washing step, the detection of the bound  
251 rabbit antibody is performed by a peroxidase labeled goat antibody anti rabbit (POD-antibody).  
252 The amount of converted substrate (TMB) is indirectly proportional to the amount of GST  
253 antigen in the sample [51]. The results are expressed as  $\mu\text{mol}$  of GST per gram of protein  
254 ( $\mu\text{mol/g prot}$ ).

#### 255 256 **2.4.3. Lipid peroxidation evaluation**

257  
258 Oxidative lesion of lipids was evaluated by the formation of a thiobarbituric acid (TBA) adduct  
259 of malondialdehyde (MDA) and then separated by HPLC [52, 53]. Cell lysates were boiled  
260 during 60 min with TBA and phosphoric acid, then were deproteinized with methanol / NaOH  
261 1M (10:1) and centrifuged. The supernatant (20  $\mu\text{l}$ ) was injected into a Spherisorb ODS2 5  $\mu\text{m}$   
262 (250 x 4.6mm) column. Elution was performed with 60% (v/v) potassium phosphate buffer 50  
263 mM, pH 6.8, and 40% (v/v) methanol at a flow rate of 1 ml/min. The TBA-MDA adducts were  
264 detected at 532 nm and quantified by extrapolating the area of the peaks from a calibration curve  
265 of 1,1,3,3-tetraetoxipropane (TEP) standard solutions. Results are expressed as  $\mu\text{mol}$  of MDA  
266 per gram of protein ( $\mu\text{mol/g prot}$ ).

#### 267 268 **2.4.4. Total Antioxidant Status (TAS) determination**

269  
270 TAS was determined by a chromogenic method (Randox Laboratories Crumham's, North  
271 Ireland) with briefly adaptations. This methodology is based on the capacity to inhibit the  
272 formation of the ABTS<sup>+</sup> radical cation (2,2'-azino-di- [3-ethylbenzotiazolin sulfonate]) and  
273 detection at 600 nm in a spectrophotometer UVIKON 933-UV / Visible, thermostated and  
274 computerized [54]. Results are expressed as  $\mu\text{mol}$  of TAS per gram of protein ( $\mu\text{mol/g prot}$ ).

275

## 276 2.5. Statistics

277  
278 Statistical analyses were carried out using t-tests. Significance was assessed for P values < 0.05.

279

## 280 3. RESULTS

281

### 282 3.1. Metastatic prostate cancer cells are more resistant to H<sub>2</sub>O<sub>2</sub> than the other cell lines

283

#### 284 3.1.1. Effect of H<sub>2</sub>O<sub>2</sub> on cell growth and viability

285 Fig.1 represents the proliferative effect of H<sub>2</sub>O<sub>2</sub> (10nM-500μM) on a cell line derived from  
286 human normal prostate epithelium (RWPE1) and on prostate cancer cells, derived from localized  
287 and metastatic carcinoma (HPV10 and PC3 respectively), during 72h. As we observe H<sub>2</sub>O<sub>2</sub>  
288 induces different effects according to cell type, time of incubation and concentration exposure.  
289 Therefore H<sub>2</sub>O<sub>2</sub> inhibits RWPE1 cell growth for all tested concentrations whereas PC3 seems to  
290 maintain a cell proliferation rate above the half maximal inhibitory concentration (IC<sub>50</sub>). On the  
291 other hand we found that low H<sub>2</sub>O<sub>2</sub> concentrations induce an increase in HPV10 cells  
292 proliferation.

293 We observed that the effect of H<sub>2</sub>O<sub>2</sub> on cell proliferation inhibition, namely at IC<sub>50</sub>  
294 concentration is associated to cell death mainly by necrosis, in HPV10 and RWPE1 cells. Data  
295 not shown, also indicate that lower ROS concentration, namely 100μM H<sub>2</sub>O<sub>2</sub>, induced necrosis  
296 in RWPE1 and HPV10. However, PC3 maintain cell viability besides a decrease in cell  
297 proliferation (Fig. 2). These results suggest a more efficient adaptation to peroxides in PC3.

298

#### 299 3.1.2. Influence of H<sub>2</sub>O<sub>2</sub> on MMP

300 To evaluate the role of mitochondria on prostate cancer progression/metastasization and the  
301 effect of H<sub>2</sub>O<sub>2</sub> on MMP we used the JC1 assay. Fig. 3 shows that PC3 cells had the highest basal  
302 MMP and RWPE the lowest, which is in line with viability and proliferative results. However, in  
303 the presence of H<sub>2</sub>O<sub>2</sub>, we observe a significant decrease in MMP, in RWPE1 and HPV10 cells, as

304 demonstrated by the increase of monomers/aggregates (M/A) ratio that also agree with viability  
305 and proliferative results.

### 306 **3.1.3. Metastatic prostate cancer cells are resistant to ROS (peroxides) by an increase in** 307 **GSH content and Gl-Red activity**

308  
309 To evaluate the role of H<sub>2</sub>O<sub>2</sub> on ROS (peroxides) production we used the 2,7  
310 dichlorodihydrofluorescein diacetate (DCFH<sub>2</sub>-DA) probe, a dye that fluoresces in the presence of  
311 peroxides (H<sub>2</sub>O<sub>2</sub>) [46].

312 This study shows that prostate cancer cells, particularly the metastatic cells (PC3), exhibit  
313 significant higher ROS levels compared with the others (Fig.4). On the other hand the sensitivity  
314 to cytotoxicity induced by ROS (H<sub>2</sub>O<sub>2</sub>) in RWPE1 and HPV10 is confirmed by an increase in  
315 lipid peroxidation as observed in Fig. 5. In opposite we found a decrease in lipid peroxidation  
316 and increase of TAS in PC3 (Fig. 5). These results suggest that PC3 cells are resistant to ROS  
317 which may contribute to a more aggressive phenotype, related with prostate progression and  
318 metastasization. In order to determine the contribution of the antioxidant system in cells  
319 adaptation to ROS, we analysed GSH and GST content and Gl-Red and Gl-Px activities,  
320 simultaneously in the three cell lines. Results represented in Fig. 6 indicate a significant decrease  
321 in GST (Fig. 6D) content and Gl-Px (Fig. 6B) activity in the malignant cells, particularly in PC3,  
322 which may be related with higher H<sub>2</sub>O<sub>2</sub> levels. On the other hand, PC3 have the highest GSH  
323 content and Gl-Red activity that could contribute to resistance to OS (Fig. 6C and 6A  
324 respectively).

325

### 326 **3.1.4. Adaptation to peroxides (ROS) is reverted by DEM**

327

328 In order to evaluate the modulation of ROS resistance by GSH content, the major thiol in  
329 mammalian cells, and Gl-Red activity, PC3 cells were treated with a thiol depleting agent  
330 (DEM), during 24h.

331 As we can observe in Fig. 7 (A1 and A2), DEM induces a decrease in GSH content and Gl-Red  
332 activity concomitantly with a decrease in cell proliferation (Fig. 7 B1) and an increase of  
333 cytotoxicity mediated by H<sub>2</sub>O<sub>2</sub> (ROS) in PC3 cells (Fig. 7C).

334 In fact, the association of DEM and 500 $\mu$ M H<sub>2</sub>O<sub>2</sub> induced a decrease in cell growth (Fig. 7 B2)  
335 and viability (Fig. 7C).when compared with 500 $\mu$ M H<sub>2</sub>O<sub>2</sub> alone. This is accompanied by an  
336 increase in cell death mainly by apoptosis and late apoptosis/necrosis after 24h treatment with  
337 DEM (Fig. 7C).

338

#### 339 4. DISCUSSION

340

341 Development of efficient therapies requires a better understanding of the mechanisms underlying  
342 prostate carcinogenesis. Although OS has been associated with prostate cancer development and  
343 progression due to an increase of ROS [7, 55], the mechanisms whereby ROS and antioxidants  
344 may induce cancer progression remain unclear [12]. As a result, greater understanding of OS  
345 may be of considerable importance for fighting prostate cancer.

346 In line with existing literature, we observed that the effect of H<sub>2</sub>O<sub>2</sub> on cell proliferation is dose,  
347 time and cell type dependent. In particular, low levels of H<sub>2</sub>O<sub>2</sub> (10-100nM) induced cell growth,  
348 in HPV10, derived from localized carcinoma, suggesting that small increments of ROS may be  
349 important in progression of prostate cancer. Interestingly, Sikka *et al.* [7] previously  
350 demonstrated that low levels of H<sub>2</sub>O<sub>2</sub> (30pM to 300nM), induce cell growth on benign prostate  
351 hyperplasia (BPH), characterized by an intense cell proliferation rate and considered as potential  
352 precursor of prostate cancer [56]. On the other hand, chronic inflammation of prostate  
353 epithelium, due to persistent ROS production, has been associated with increase of OS and DNA  
354 damage leading to neoplastic transformation (for a good review of this literature see Nelson *et al.*  
355 [19]). However, an excess of ROS is expected to be harmful and to induce apoptosis in several  
356 human tumour cell lines [19]. Here we found that 500 $\mu$ M H<sub>2</sub>O<sub>2</sub> inhibits cell proliferation in all  
357 the tested cells lines, but the effect was less pronounced in PC3. These differences may be  
358 notably observed after 72h of treatment.

359 Moreover it was accompanied by cell death, essentially by necrosis, in HPV10 and in the normal  
360 epithelium cell line, RWPE1 just after 24h treatment. Similar results were found by Sika *et al.*  
361 [7] in BPH cell lines with 300 $\mu$ M H<sub>2</sub>O<sub>2</sub>. However, higher H<sub>2</sub>O<sub>2</sub> concentrations did not affect PC3  
362 viability that appears to be more resistant to OS. It would be interesting to evaluate whether  
363 H<sub>2</sub>O<sub>2</sub> causes some cycle phase-specific blockade, since drug-provoked oxidative stress causes  
364 cell cycle disruption as well as cell death. This may also be important in cancer treatment.

365 We observed the highest basal levels of ROS in PC3 (Fig. 4) which may be related to cells  
366 resistance to H<sub>2</sub>O<sub>2</sub> induced cytotoxicity and to a more aggressive phenotype, although others  
367 have found that increase of ROS is related with cell injury, resulting from oxidative damage of  
368 biomolecules such as DNA, proteins and lipids [3-12, 34, 35]. It is also important to realize that  
369 tumor progression is based on DNA mutations which promote cancer cells proliferation and  
370 surveillance [57]. In part, these mutations may be acquired as a result of an increase of ROS  
371 which require an antioxidant system adaptation [58].

372 Viability results are in line with MMP detected in cells. In fact, at basal conditions, PC3 cells  
373 show the highest MMP whereas RWPE1 cells show the lowest MMP. These results may be  
374 related with cell vulnerability to ROS induced cytotoxicity. In the same way, when PC3 were  
375 treated with 500µM H<sub>2</sub>O<sub>2</sub> we didn't observe a significant decrease in MMP, in contrast to other  
376 cell lines. Based on this evidence we also suggest that variation in MMP is related to cell growth  
377 but not in a directly proportional ratio.

378 In order to better understand the effect of OS in prostate cancer progression we evaluated the  
379 levels of ROS and antioxidant defences among the distinct cell lines. We found that ROS levels  
380 are lower in RWPE1 and substantially higher in PC3 as we have previously referred. These  
381 findings are in agreement with those observed by Kumar *et al.* [55]. The same authors show that  
382 the degree of ROS generation is directly proportional to aggressive phenotype. They also found  
383 higher levels of ROS in PC3 compared to RWPE1, although, they did not analyse localized  
384 prostate cancer cell lines as performed in our work. Likewise we demonstrate that HPV10 cells  
385 show intermediate ROS levels. These cells also represent an intermediate stage (localized  
386 cancer) between RWPE1 and PC3 cells. Kumar *et al.* [55] also demonstrated that ROS, mainly  
387 generated by the Nox system (trans-membrane proteins called the NADPH oxidases), is essential  
388 for deregulated growth, colony formation, cell migration and invasion and contribute to tumour  
389 metastization. Besides the increase of ROS levels in PC3 cells, we found lower levels of lipid  
390 peroxidation (MDA) and higher levels of TAS that are consistent with cell resistance to OS.  
391 Therefore, these results suggest that PC3 cells counteract OS by expressing particular free radical  
392 scavengers. In fact, we found significant increase of GSH and Gl-Red activity in PC3 that may  
393 protect these cells under persistent ROS (peroxides) production, induced by radiotherapy and  
394 chemotherapy. H<sub>2</sub>O<sub>2</sub> treatment induced a clear decrease in TAS that is in agreement with the  
395 increase of MDA. These observations may be due to the absence of a significant increase in the

396 antioxidant defences, in face of the H<sub>2</sub>O<sub>2</sub> insult. On the other hand it may be explained by the  
397 high basal levels of GSH content and Gl-Red activity observed in PC3. However, we may  
398 consider other explanations for the observed decrease of TAS and increase of MDA. Namely, as  
399 TAS evaluation is based on the antioxidants capacity to inhibit ABTS<sup>+</sup> radical cation (2,2'-azino-  
400 di- [3-ethylbenzotiazolin sulfonate])[42] and that the antioxidant system may be recruited to face  
401 the increase of H<sub>2</sub>O<sub>2</sub>, we admit that the antioxidant defences are unavailable to inhibit ABTS<sup>+</sup>,  
402 leading to TAS reduction observations. Moreover, the antioxidant system comprises other  
403 antioxidant defences like catalase, playing an important role in neutralizing H<sub>2</sub>O<sub>2</sub>, or superoxide  
404 dismutase and  $\alpha$ -tocopherol (that protects from lipid peroxidation), which we didn't analyzed  
405 that may also contribute to explain the decrease of TAS and increase of MDA.

406 In contrast, Gl-Px activity and GST are depleted in PC3 suggesting that GST depletion may  
407 facilitate prostate cancer progression as described by others [8]. The same assumption may be  
408 addressed to Gl-Px activity.

409 GSH, the major thiol in mammalian cells, maintains an optimum cellular redox potential trough  
410 the inactivation of H<sub>2</sub>O<sub>2</sub>. The contribution of GSH and Gl-Red in PC3 cells protection against  
411 ROS was also suggested by Lim *et al.* [9]. These authors compared two metastatic prostate  
412 cancer cells, LNCaP, and PC3 and found lower ROS levels in PC3 that could be explained by an  
413 increase of GSH content, Gl-Red, thioredoxin reductase (TR) and GST activities. However,  
414 Kumar *et al.* [55] contradict those results showing higher ROS levels in PC3 comparing to  
415 LNCaP. In our study, PC3 Gl-Red activity is in the range values found by Jung *et al.* [3]. These  
416 authors also reported an increase in Gl-Red and a decrease in GST and Gl-Px activities in  
417 metastatic prostate cancer cells (PC3, LNCaP and DU145) comparing with primary cell cultures  
418 of benign and malignant human prostatic tissue. They also show higher Gl-Px and lower Gl-Red  
419 activities in PC3 cells comparing to other metastatic cell lines, reinforcing our observations that  
420 Gl-Px is decreased and Gl-Red is increased in advanced tumours cells. Therefore Gl-Red may  
421 contribute to protection against ROS.

422 To confirm the role of GSH content and Gl-Red activity in the adaptation to OS by metastatic  
423 prostate cancer cells, we treat the cells with DEM, a thiol depletion agent. Our study revealed  
424 that cells treated with 50 $\mu$ M DEM alone show a decrease in Gl-Red activity, additionally to a  
425 decrease in GSH content (Fig 7A1) with no interference on cell proliferation and death.  
426 However, in the presence of H<sub>2</sub>O<sub>2</sub> the decrease in Gl-Red activity and GSH content was

427 accomplished by a decrease in cell proliferation and increase of cell death preferentially by  
428 apoptosis and late apoptosis/necrosis. GSH reduction in the presence of DEM is in agreement  
429 with the results obtained by Coffey *et al.* [59,60]. These authors show an increase of apoptosis  
430 induced by radiation, in the presence of DEM, in PC3 and in other metastatic prostate cancer  
431 cells, LNCaP and DU145. They also found that apoptosis is accompanied by an efflux of GSH  
432 from the nucleus to the cytosol and admit that the presence of GSH in the nucleus may offer  
433 resistance to apoptosis.

434 Here we strongly proved that Gl-Red activity reduction participates in the increase of H<sub>2</sub>O<sub>2</sub>  
435 toxicity in metastatic prostate cancer cells, suggesting a potential therapeutic approach. It may be  
436 also related with GSH reduction as observed here and by others [59,60]. These results also  
437 conduct to the possibility of using other Gl-Red activity reducing agents or to evaluate the  
438 combined effect of DEM with conventional chemotherapeutic drugs, namely docetaxel,  
439 expecting that the association may allow to lowering drug concentrations, therefore reducing  
440 drug side effects, related with systemic toxicity. In fact we previously found that sodium  
441 selenite, a thiol depleting agent, combined with docetaxel, play a synergistic effect on PC3 cells  
442 growth inhibition and induces cell death [38] Likewise our study warrants further evaluation of  
443 oxidative stress modulation in prostate cancer therapeutic approach. In particular, it would be  
444 interesting to evaluate the effect of DEM-produced GSH depletion and Gl-Red reduced activity  
445 in the RWPE cells, in order to evaluate the potential toxicity in non tumour cells.

446

## 447 5. CONCLUSIONS

448

449 As described above, other reports have compared the relative efficacy of antioxidant system in  
450 prostate cancer. However, this work develops a more graded study by including models  
451 representative of different stages of prostate malignancy.

452 To our knowledge, our study performed on cell lines representing normal prostate epithelium,  
453 localized and metastatic prostate cancer, all stages of prostate cancer progression, is the first  
454 demonstrating an increase of ROS (peroxides) along with prostate cancer progression,  
455 concomitantly with OS adaptation. Therefore we suggest that this duality may be necessary for  
456 prostate cancer progression and for a more aggressive malignant phenotype. On the other hand,

457 as normal epithelium cell line shows lower ROS levels in basal conditions, but greater sensitivity  
458 to cytotoxicity induced by ROS (500 $\mu$ M H<sub>2</sub>O<sub>2</sub>) and concomitantly lower GSH levels and GI-Red  
459 activity, these conditions may contribute to a higher susceptibility to OS lesion by normal  
460 prostate epithelium.

461 The cell line model, presented here shows an important approach to understanding oxidative  
462 stress through the different stages of prostate cancer. However, it is possible that cell lines do not  
463 exactly reflect the true in vivo situation. We also realize that the present strategy, developed in a  
464 cell line model, may not be efficient when applied to in vivo experiments. Different culture  
465 conditions could influence the observed results. However, this study does propose oxidative  
466 stress modulation as a possible new therapeutic approach in prostate cancer. We intend to carry  
467 out further evaluation of this strategy to in vivo model.

468 Furthermore, as far as we are aware, we are the first to confirm the pivotal role of GI-Red's  
469 activity as a new target-directed therapeutic tool in the treatment of prostate cancer.

470

## 471 **6. ACKNOWLEDGMENTS AND FUNDING**

472

473 This work was supported by the CIMAGO - Centre of Investigation in Environment, Genetics  
474 and Oncobiology, Faculty of Medicine, University of Coimbra [Grant CIMAGO 14/05; Grant  
475 CIMAGO 3/06] and the Fundação para a Ciência e a Tecnologia (FCT), Portugal [Grant  
476 SFRH/BD/40215/2007].

477

## 478 **7. REFERENCES**

479

480 [1] Jemal, A; Siegel, R; Ward, E; Hao, Y; Xu, J; Murray, T & Thun, MJ. (2008). Cancer  
481 Statistics 2008. CA Cancer J Clin. 587, 71-96.

482

483 [2] Jemal, A; Siegel, R; Xu, J & Ward, E. (2010). Cancer Statistics 2010. CA Cancer J Clin.  
484 60(5), 277-300.

485

486 [3] Jung, K; Seidel, B; Rudolph, B; Lein, M; Cronauer, MV; Henke, W; Hampel, G; Schnorr, D

487 & Loening, SA. (1997). Antioxidant enzymes in malignant prostate cell lines and in primary  
488 cultured prostatic cells. *Free Radic Biol Med.* 23, 127-133.

489  
490 [4] Baker, AM; Oberley, LW & Cohen, MB. (1997). Expression of antioxidant enzymes in  
491 human prostatic adenocarcinomas. *Prostate.* 32, 229-233.

492  
493 [5] Oberley, TD; Zhong, W; Szweda, LI & Oberley, LW. (2000). Localization of antioxidant  
494 enzymes and oxidative damage products in normal and malignant prostate epithelium. *Prostate.*  
495 44, 144-155.

496  
497 [6] Bostwick, DG; Alexander, EE; Singh, R; Shan, A; Qian, J; Santella, RM; Oberley, LW; Yan  
498 T; Zhong, W; Jiang, X & Oberley, TD. (2000). Antioxidant enzyme expression and reactive  
499 oxygen species damage in prostatic intraepithelial neoplasia and cancer. *Cancer.* 89, 123-134.

500  
501 [7] Sikka, SC. (2003). Role of oxidative stress response elements and antioxidants in prostate  
502 cancer pathobiology and chemoprevention-a mechanistic approach. *Curr Med Chem.* 10(24),  
503 2679-2692.

504  
505 [8] Trzeciak, AR; Nyaga, SG; Jaruga, P; Lohani, A; Dizdaroglu, M & Evans, MK. (2004).  
506 Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines  
507 PC-3 and DU-145. *Carcinogenesis.* 25, 1359-1370.

508  
509 [9] Lim, HW; Hong, S; Jin, W; Lim, S; Kim, SJ; Kang, HJ; Park, EH; Ahn, K & Lim, CJ.  
510 (2005). Up-regulation of defense enzymes is responsible for low reactive oxygen species in  
511 malignant prostate cancer cells. *Exp Mol Med.* 37(5), 497-506.

512  
513 [10] Venkataraman, S; Jiang, X; Weydert, C; Zhang, Y; Zhang, HJ; Goswami, PC; Ritchie, JM;  
514 Oberley, LW & Buettner, GR. (2005). Manganese superoxide dismutase overexpression inhibits  
515 the growth of androgen-independent prostate cancer cells. *Oncogene.* 24, 77-89.

516  
517 [11] Aydin, A; Arsova-Sarafinovska, Z; Sayal, A; Eken, A; Erdem, O; Erten, K; Ozgök Y &

- 518 Dimovski, A. (2006). Oxidative stress and antioxidant status in non-metastatic prostate cancer  
519 and benign prostatic hyperplasia. *Clin Biochem.* 39, 176-179.
- 520
- 521 [12] Yossepowitch, O; Pinchuk, I; Gur, U; Neumann, A; Lichtenberg, D & Baniel, J. (2007).  
522 Advanced but not localized prostate cancer is associated with increased oxidative stress. *J Urol.*  
523 178 (4), 1238-1244.
- 524
- 525 [13] Sies, H. (1985). Oxidative Stress: Introductory remarks. In: *Oxidative Stress* (Sies H, eds),  
526 pp. 1-8. Academic Press, London.
- 527
- 528 [14] Sies, H. (1997). Oxidative stress: oxidants and antioxidants. *Exp Physiol.* 82(2), 291-295.
- 529
- 530 [15] Shimizu, H; Ross, RK; Bernstein, L; Yatani, R; Henderson, BE & Mack, TM. (1991).  
531 Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles  
532 County. *Br J Cancer.* 63, 963-966.
- 533
- 534 [16] Whittemore, AS; Kolonel, LN; Wu, AH; John, EM; Gallagher, RP; Howe, GR; Burch, JD;  
535 Hankin, J; Dreon, DM; West, DW; Teh, C-Z & Paffenbarger, RS. (1995). Prostate cancer in  
536 relation to diet physical activity and body size in blacks whites and Asians in the United States  
537 and Canada. *J Natl Cancer Inst.* 87, 652-661.
- 538
- 539 [17] Gronberg, H. (2003). Prostate cancer epidemiology. *Lancet.* 361, 859-864.
- 540
- 541 [18] Jian, L; Xie, P; Lee, AH & Binns, CW. (2004). Protective effect of green tea against  
542 prostate cancer: A case-control study in southeast China. *Int J Cancer.* 108, 130-135.
- 543
- 544 [19] Nelson, WG; DeWeese, TL & DeMarzo, AM. (2002). The diet inflammation and the  
545 development of prostate cancer. *Cancer Metastasis Rev.* 21, 3-16.
- 546
- 547 [20] De Marzo, AM; Platz, EA; Sutcliffe, S; Xu, J; Grönberg, H; Drake, CG; Nakai, Y; Isaacs,  
548 WB & Nelson, WG. (2007). Inflammation in prostate carcinogenesis. *Nature Rev Cancer.* 7,

549 256-269.

550

551 [21] Kwabi-Addo, B; Chung, W; Shen, L; Ittmann, M; Wheeler, T; Jelinek, J & Issa, J-P. (2007).  
552 Age-related DNA methylation changes in normal human prostate tissues. *Clin Cancer Res.*13,  
553 3796-3802.

554

555 [22] Halliwell, B & Gutteridge, JMC. (1990). Role of free radicals and catalytic metal ions in  
556 human disease: an overview. *Methods Enzymol.* 186, 1-85.

557

558 [23] Aruoma, OI. (1998). Free radicals oxidants and antioxidants: trend towards the year 2000  
559 and beyond. In *Molecular Biology of Free Radicals in Human Diseases* (Aruoma O I & Halliwell  
560 B eds), pp. 1-28. OICA International St. Lucia, London.

561

562 [24] Sundaresan, M; Yu, ZX; Ferrans, VJ; Irani, K & Finkel, T. (1995). Requirement for  
563 generation of H<sub>2</sub>O<sub>2</sub> for platelet-derived growth factor signal transduction. *Science.* 270, 296-299.

564

565 [25] Murrell, GA; Francis, MJ; Bromley, L. (1990). Modulation of fibroblast proliferation by  
566 oxygen free radicals. *Biochem J.* 265(3), 659-665.

567

568 [26] Burdon, RH. (1995). Superoxide and hydrogen peroxide in relation to mammalian cell  
569 proliferation. *Free Radic Biol Med.* 18, 775-794.

570

571 [27] del Bello, B; Paolicchi, A; Comporti, M; Pompella, A & Maellaro, E. (1999). Hydrogen  
572 peroxide produced during gamma-glutamyl transpeptidase activity is involved in prevention of  
573 apoptosis and maintenance of proliferation in U937 cells. *FASEB J.* 13(1), 69-79.

574

575 [28] Sauer, H; Wartenberg, M & Hescheler, J. (2001). Reactive oxygen species as intracellular  
576 messengers during cell growth and differentiation. *Cell Physiol Biochem.* 11, 173-186.

577

578 [29] Courtney, G; Havens, AH; Naohisa, Y & Steven, FD. (2006). Regulation of Late G1/S  
579 Phase Transition and APCCdh1 by Reactive Oxygen Species. *Mol Cell Biol.* 26(12), 4701-4711.

- 580
- 581 [30] Boonstra, J & Post, JA. (2004). Molecular events associated with reactive oxygen species  
582 and cell cycle progression in mammalian cells. *Gene*. 337, 1-13.
- 583
- 584 [31] Chandel, NS; Maltepe, E; Goldwasser, E; Mathieu, CE; Simon, MC & Schumacker, PT.  
585 (1998). Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. *Proc Natl*  
586 *Acad Sci USA*. 95, 11715-11720.
- 587
- 588 [32] Allen, RG & Balin, AK. (1989). Oxidative influence on development and differentiation: an  
589 overview of a free radical theory of development. *Free Radic Biol Med*. 6(6), 631-661.
- 590
- 591 [33] Martindale, JL & Holbrook, NJ. (2002). Cellular response to oxidative stress: signalling for  
592 suicide and survival. *J Cell Physiol*. 192, 1-15.
- 593
- 594 [34] Suzuki, Y; Kondo, Y; Himeno, S; Nemoto, K; Akimoto, M & Amura, N. (2000). Role of  
595 Antioxidant Systems in Human Androgen-Independent Prostate Cancer Cells. *Prostate*. 43, 144-  
596 149.
- 597
- 598 [35] Shackelford, RE; Kaufmann, WK & Paules, RS. (2000). Oxidative stress and cell cycle  
599 checkpoint function. *Free Radic Biol Med*. 28, 1387-1404.
- 600
- 601 [36] Guyton, KZ & Kensler, TW. (1993). Oxidative mechanisms in carcinogenesis. *Br Med Bull*.  
602 49(3), 523-544.
- 603 [37] Haimovitz-Friedman, A. (1998). Radiation-induced signal transduction and stress response.  
604 *Radiat Res*. 150, 102-108.
- 605
- 606 [38] Freitas, M; Alves, V; Sarmiento-Ribeiro, AB & Mota-Pinto, A. (2011). Combined effect of  
607 sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line. *Biochem Biophys Res*  
608 *Commun*. 408, 713-719.
- 609
- 610 [39] Kaighn, ME; Narayan, KS; Ohnuki, Y; Lechner, JF & Jones, LW. (1979). Establishment

- 611 and characterization of a human prostatic carcinoma cell line (PC3). *Invest Urol.* 17(1), 16-23.  
612
- 613 [40] Weijerman, PC; König, JJ; Wong, ST; Niesters, HG & Peehl, DM. (1994). Lipofection-  
614 mediated immortalization of human prostatic epithelial cells of normal and malignant origin  
615 using human papillomavirus type 18 DNA. *Cancer Res.* 54(21), 5579-5583.  
616
- 617 [41] Bello, D; Webber, MM; Kleinman, HK; Wartinger, DD & Rhim, JS. (1997). Androgen  
618 responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.  
619 *Carcinogenesis.* 18, 1215-1223.  
620
- 621 [42] Alley, MC; Scudiero, DA; Monks, A; Hursey, ML; Czerwinski, MJ; Fine, DL; Abbot, BJ;  
622 Mayo, JG; Shoemaker, RH & Boyd, MR. (1998). Feasibility of drug screening with panels of  
623 human tumour cell lines using a microculture tetrazolium assay. *Cancer Res.* 48(3), 589-601.  
624
- 625 [43] Boldyrev, AA. (2000). Discrimination between apoptosis and necrosis of neurons under  
626 oxidative stress. *Biochemistry (Mosc).* 65, 834-842.  
627
- 628 [44] Cossarizza, A; Baccarini-Contri, M; Kalashnikova, G & Franceschi, C. (1993). A new  
629 method for the cytofluorimetric analysis of mitochondrial membrane potential using J-aggregate  
630 forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine  
631 iodide (JC-1). *Biochem Biophys Res Commun.* 197, 40-45.  
632
- 633 [45] Rothe, G & Valet, G. (1990). Flow cytometric analysis of respiratory burst activity in  
634 phagocytes with hydroethidine and 2,7 dichlorofluorescein. *J Leukoc Biol.* 47(5), 440-448.  
635
- 636 [46] Lee, HC; Yin, PH; Lu, CY; Chi, CW & Wei, YH. (2000). Increase of mitochondria and  
637 mitochondrial DNA in response to oxidative stress in human cells. *Biochem J.* 348, 425-432.  
638
- 639 [47] Gao, F; Yi, J; Yuan, JQ; Shi, GY & Tang, XM. (2004). The cell cycle related apoptotic  
640 susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. *Cell Res.*  
641 14, 81-85.

- 642
- 643 [48] Tsao, S-M; Yin, M-C & Liu, W-H. (2007). Oxidant stress and B vitamins status in patients  
644 with non-small cell lung cancer. *Nutr Cancer*. 59(1), 8-13.
- 645
- 646 [49] Plagia, DE & Valentine, WN. (1967). Studies on the quantitative and qualitative  
647 characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med*. 70, 158-169.
- 648
- 649 [50] Goldberg, DM & Spooner, RJ. (1983). Glutathione reductase. In *Methods in Enzymatic*  
650 *Analysis* (Bergmeyer UH eds), pp. 258-265 Verlag Chemie Weinheim Academic Press, New  
651 York.
- 652
- 653 [51] Kullich, W; Fagerer, N & Schwann, H. (2007). Effect of the NSAID nimesulide on the  
654 radical scavenger glutathione-S-transferase in patients with osteoarthritis of the knee. *Curr Med*  
655 *Res Opin*. 23(8), 1981-1986.
- 656
- 657 [52] Knight, JA; Pieper, RK & McClellan, L. (1998). Specificity of the thiobarbituric acid  
658 reaction: its use in studies of lipid peroxidation. *Clin Chem*. 34(12), 2433-2438.
- 659
- 660 [53] Draper, HH & Hadley, M. (1990). Malondialdehyde determination as an index of lipid  
661 peroxidation. *Methods Enzymol*. 186, 421- 431.
- 662
- 663 [54] Miller, JK; Brzezinska-Slebodzinska, E & Madsen, FC. (1993). Oxidative stress  
664 antioxidants and animal function. *J Dairy Sci*. 76, 2812-2823.
- 665
- 666 [55] Kumar, B; Koul, S; Khandrinka, L; Meacham, RB & Koul, HK. (2008). Oxidative stress is  
667 inherent in prostate cancer cells and is required for aggressive phenotype. *Cancer Res*. 68(6),  
668 1777-1785.
- 669
- 670 [56] Mishina, T; Watanabe, H; Araki, H & Nakao, M. (1985). Epidemiological study of prostatic  
671 cancer by matched-pair analysis. *Prostate*. 6, 423-46.
- 672

673 [57] Loeb, KR & Loeb, LA. (2000). Significance of multiple mutations in cancer.  
674 Carcinogenesis. 21(3), 379-385.

675  
676 [58] Khandrika, L; Kumar, B; Koul, S; Maroni, P; Koul, HK. (2009). Oxidative stress in prostate  
677 cancer. Cancer Lett. 282(2), 125-136.

678  
679 [59] Coffey, RNT; Watson, RWG; Hegarty, NJ; O'Neill, A; Gibbons, N; Brady, HR; &  
680 Fitzpatrick, JM. (2000). Thiol mediated apoptosis in prostate carcinoma cells. Cancer. 88(9),  
681 2092-2104.

682  
683 [60] Coffey, RNT; Watson, RWG; Hegarty, PK; Watson, CL; Woloham, L; Brady, HR;  
684 O'Keane, C & Fitzpatrick, JM. (2001). Priming prostate cancer cells for increased apoptosis is  
685 associated with up-regulation of the caspases. Cancer. 92(9), 2297-2308.

## 686 687 **8. FIGURE LEGENDS**

688  
689 **FIGURE 1. Dose-response curves.** The effect of different H<sub>2</sub>O<sub>2</sub> concentrations (10nM–500μM)  
690 on proliferation of human normal prostate epithelium (RWPE1) and prostate cancer cells,  
691 derived from localized and metastatic carcinoma (HPV10 and PC3) are represented. Proliferation  
692 was evaluated through the formation of formazan products by 3-(4,5-dimethylthiazol-2-yl)-2,5-  
693 diphenyltetrazolium bromide (MTT), each 24h, during 72 hours of incubation, as refereed in  
694 materials and methods. Results are expressed as percentage of MTT reduction relatively to  
695 control (cells not treated with H<sub>2</sub>O<sub>2</sub>) and correspond to the mean ± SD of at least 3 separate  
696 experiments.

697  
698 **FIGURE 2. Effect of H<sub>2</sub>O<sub>2</sub> on cell viability and death in RWPE1, HPV10 and PC3 cells.**  
699 Dot-plot profiles (1) were obtained after the acquisition of 10 000 events. Cells cultured in the  
700 absence (untreated) or in the presence of 500μM H<sub>2</sub>O<sub>2</sub> during 24 hours. Cells were incubated  
701 with AnnexinV/IP as refereed in materials and methods. Alive cells (A) exclude propidium  
702 iodide and do not bind annexin-V. Apoptotic cells with intact membranes exclude propidium

703 iodide, externalize phosphatidylserine to the outside of the plasma membrane and therefore bind  
704 Annexin V (IA) emitting fluorescence. Propidium iodide stains nuclear DNA of necrotic (N) and  
705 late apoptosis/necrosis cells (LA/N).

706 Results were expressed as the percentage of cells staining with the respective molecular probe  
707 (2). The results represent the means  $\pm$  SD of at least triplicate determinations. Significantly  
708 viability and necrosis differences are considered: \*\*\* $p < 0.001$  vs untreated samples, ### $p < 0.001$   
709 for PC3 and HPV10 vs RWPE1 and +++ $p < 0.001$  for PC3 vs HPV10.

710  
711 **FIGURE 3. MMP evaluation in RWPE1, HPV10 and PC3 cells.** Dot-plot profiles (1) were  
712 obtained after the acquisition of 10 000 events. RWPE1, HPV10 and PC3 cells were cultured in  
713 the absence (untreated) or in the presence of 500 $\mu$ M H<sub>2</sub>O<sub>2</sub> for 24 hours. The MMP was assessed  
714 by flow cytometry labelling the cells with the molecular probes JC1 as described in materials and  
715 methods. Results were expressed as the ratio of Monomers/Aggregates (M/A) (which are  
716 inversely proportional to MMP) and represent the means MMP  $\pm$  SD of at least triplicate  
717 determinations (2). Significantly viability differences are considered: \*\*\* $p < 0.001$  vs untreated  
718 samples, ### $p < 0.001$  and # $p < 0.01$  for PC3 and HPV10 vs RWPE1 and + $p < 0.05$  for PC3 vs  
719 HPV10.

720  
721 **FIGURE 4. Effect of H<sub>2</sub>O<sub>2</sub> on ROS production in RWPE1, HPV10 and PC3 cells.** Dot-plot  
722 profiles (1) were obtained after the acquisition of 10 000 events. RWPE1, HPV10 and PC3 cells  
723 were cultured in the absence (untreated) or in the presence of 500 $\mu$ M H<sub>2</sub>O<sub>2</sub> for 24 hours. ROS  
724 was assessed by flow cytometry labelling the cells with 2,7 dichlorodihydrofluorescein diacetate  
725 (DCFH<sub>2</sub>-DA). The results were expressed as the means intensity fluorescence (MIF)  $\pm$  SD of at  
726 least triplicate determinations (2). Significantly differences are considered: \* $p < 0.05$  vs untreated  
727 samples, # $p < 0.01$ , ### $p < 0.001$  for PC3 and HPV10 vs RWPE1 and +++ $p < 0.001$  for PC3 vs  
728 HPV10.

729  
730 **FIGURE 5. Evaluation of lipid peroxidation and TAS in RWPE1, HPV10 and PC3 cells**  
731 Cells were treated with 500 $\mu$ M H<sub>2</sub>O<sub>2</sub> for 24 hours as described in materials and methods. Lipid  
732 peroxidation (A) was evaluated by MDA determination levels. MDA and TAS (B) levels were  
733 detected according with described in material and methods. Results were expressed as the means

734  $\pm$  SD of at least triplicate determinations. Significant differences are considered: \* $p < 0.05$  vs  
735 untreated samples, # $p < 0.05$ , ## $p < 0.01$ , ### $p < 0.001$  for HPV10 and PC3 vs RWPE1 and + $p < 0.05$ ,  
736 ++ $p < 0.01$  for PC3 vs HPV10.


737  
738 **FIGURE 6. Antioxidant defences in RWPE1, HPV10 and PC3 cells.** We evaluate Gl-Red (A)  
739 and Gl-Px (B) activities and GSH (C) and GST (D) content. Cells were treated with 500 $\mu$ M  
740 H<sub>2</sub>O<sub>2</sub> for 24 hours as described in materials and methods. Results are expressed as the means  $\pm$   
741 SD of at least triplicate determinations. Significant differences are considered for \* $p < 0.05$ ,  
742 \*\* $p < 0.01$  vs untreated samples, # $p < 0.05$ , ## $p < 0.01$ , and ### $p < 0.001$  for HPV10 and PC3 vs  
743 RWPE1 and + $p < 0.05$  and +++ $p < 0.001$  for PC3 vs HPV10.

744  
745 **FIGURE 7. Effect of DEM on PC3 antioxidant defences -relation with cell proliferation**  
746 **and viability.** GSH content (A1) and Gl-Red activity (A2) on PC3 were analysed after treating  
747 cells with 50 $\mu$ M DEM for 24 hours. The effect of DEM (50 $\mu$ M -1000 $\mu$ M) alone (B1) and  
748 combined with 500 $\mu$ M H<sub>2</sub>O<sub>2</sub> (B2) on PC3 cells growth was evaluated during 72h. In (C) is  
749 represented the influence of DEM on PC3 cell viability and death. Cells were treated with  
750 500 $\mu$ M H<sub>2</sub>O<sub>2</sub>, in the absence (control) and in the presence of 50 $\mu$ M DEM for 24 hours. Viability  
751 was assessed by flow cytometry as previously described. Viable cells are expressed by alive cells  
752 (A), initial apoptosis by (IA), necrosis (N) and late by apoptosis/necrosis (LA/N).  
753 Results were expressed as the means  $\pm$  SD of at least triplicate determinations. Significant  
754 differences are considered for \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.005$  vs control. Cell viability and  
755 death statistical results are indicated for (IA) and (LA/N).

756

757 **9. FIGURES**


1





758




ACCEPTED

1



2





761 **Highlights**

762           Oxidative stress was evaluated on a cell line model of prostate cancer progression

763

764           Metastatic cell lines show the highest ROS, total antioxidant status and resistance to H<sub>2</sub>O<sub>2</sub>

765

766           Metastatic cell lines show the highest levels of GSH levels and Gl-Red activity

767

768           Decrease in GSH levels and Gl-Red activity induced a decrease in H<sub>2</sub>O<sub>2</sub> resistance

769

770           Gl-Red activity reduction may be a new therapeutic approach in prostate cancer

771

772

773